Ginkgo Bioworks Holdings, Inc.
DNA
$7.71
-$0.14-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.47M | 33.40M | 38.84M | 49.60M | 38.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.47M | 33.40M | 38.84M | 49.60M | 38.23M |
| Cost of Revenue | 3.10M | 7.30M | 12.80M | 14.82M | 4.09M |
| Gross Profit | 16.38M | 26.10M | 26.04M | 34.78M | 34.14M |
| SG&A Expenses | 37.83M | 46.01M | 44.95M | 43.28M | 41.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.85M | 103.44M | 127.11M | 111.47M | 116.96M |
| Operating Income | -71.37M | -70.05M | -88.27M | -61.87M | -78.73M |
| Income Before Tax | -76.14M | -81.39M | -80.75M | -60.58M | -83.22M |
| Income Tax Expenses | -80.00K | -643.00K | 1.00K | -283.00K | 88.00K |
| Earnings from Continuing Operations | -76.06M | -80.75M | -80.76M | -60.30M | -83.31M |
| Earnings from Discontinued Operations | -6.53M | -- | -- | -- | -7.65M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.59M | -80.75M | -80.76M | -60.30M | -90.96M |
| EBIT | -71.37M | -70.05M | -88.27M | -61.87M | -78.73M |
| EBITDA | -62.78M | -61.08M | -88.10M | -41.37M | -68.10M |
| EPS Basic | -1.39 | -1.41 | -1.45 | -1.10 | -1.68 |
| Normalized Basic EPS | -0.72 | -0.68 | -0.93 | -0.65 | -0.83 |
| EPS Diluted | -1.39 | -1.42 | -1.45 | -1.10 | -1.68 |
| Normalized Diluted EPS | -0.72 | -0.68 | -0.93 | -0.65 | -0.83 |
| Average Basic Shares Outstanding | 59.56M | 57.08M | 55.63M | 54.86M | 54.24M |
| Average Diluted Shares Outstanding | 59.56M | 57.08M | 55.63M | 54.86M | 54.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |